ArticleCancer medicine2026

Acalabrutinib Versus Venetoclax Plus Obinutuzumab in Treatment-Naive Chronic Lymphocytic Leukemia: A Real-World Propensity Score-Matched Study.

Po-Wei Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.